Afatinib

Active ingredient: Afatinib Dimaleate

In short: Afatinib tablets are indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test . Limitat

Forms & strengths• Afatinib tablets, 40 mg are white to off white, round, biconvex, bevel-edged, film-coated tablets debossed with “A40” on one side and “H” on the other side. …
LabelCamber Pharmaceuticals, Inc.
Label updatedSep 04, 2026

What is Afatinib used for?

Afatinib tablets are indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test

.

Limitations of Use: The safety and efficacy of afatinib tablets have not been established in patients whose tumors have resistant EGFR mutations .

Afatinib tablets are indicated for the treatment of patients with metastatic squamous NSCLC progressing after platinum-based chemotherapy.

Afatinib dosage

Select patients for first-line treatment of metastatic NSCLC with afatinib tablets based on the presence of non-resistant EGFR mutations in tumor specimens . Information on FDA-approved tests for the detection of EGFR mutations in NSCLC is available at:

http://www.fda.gov/CompanionDiagnostics.

The recommended dosage of afatinib tablets is 40 mg orally once daily until disease progression or no longer tolerated by the patient.

Take afatinib tablets at least 1 hour before or 2 hours after a meal.

Do not take a missed dose within 12 hours of the next dose.

Withhold afatinib tablets for:

• Grade* 3 or higher adverse reactions

• Diarrhea of Grade 2 persisting for 2 or more consecutive days while taking anti-diarrheal medication

• Cutaneous reactions of Grade 2 that are prolonged (lasting more than 7 days) or intolerable

*National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v 3.0

Resume treatment when the adverse reaction fully resolves, returns to baseline, or improves to Grade 1. Reinstitute afatinib tablets at a reduced dose, i.e., 10 mg per day less than the dose at which the adverse reaction occurred.

Permanently discontinue afatinib tablets for:

• Life-threatening bullous, blistering, or exfoliating skin lesions

• Confirmed interstitial lung disease (ILD)

• Severe drug-induced hepatic impairment

• Gastrointestinal perforation

• Persistent ulcerative keratitis

• Symptomatic left ventricular dysfunction

• Severe or intolerable adverse reaction occurring at a dose of 20 mg per day

The recommended dosage of afatinib tablets in patients with pre-existing severe renal impairment (estimated glomerular filtration rate [eGFR*] 15 to 29 mL/min/1.73 m2) is 30 mg orally once daily .

*Use the Modification of Diet in Renal Disease [MDRD] formula to estimate eGFR.

P-glycoprotein Inhibitors

Reduce afatinib tablets daily dose by 10 mg if not tolerated for patients who require therapy with a P-glycoprotein (P-gp) inhibitor. Resume the previous dose after discontinuation of the P-gp inhibitor as tolerated .

P-glycoprotein Inducers

Increase afatinib tablets daily dose by 10 mg as tolerated for patients who require chronic therapy with a P-gp inducer. Resume the previous dose 2 to 3 days after discontinuation of the P-gp inducer .

How to take Afatinib — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Diarrhea

Advise patients that diarrhea occurs in nearly all patients who receive afatinib tablets. Inform patients that diarrhea may result in dehydration and renal impairment if not treated. Advise patients to notify their physician if diarrhea develops and to seek medical attention promptly for severe or persistent diarrhea .

Bullous and Exfoliative Skin Disorders

Advise patients to minimize sun exposure with protective clothing and use of sunscreen while taking afatinib tablets .

Interstitial Lung Disease

Advise patients to immediately report any new or worsening lung symptoms, or any combination of the following symptoms: trouble breathing or shortness of breath, cough, fever

.

Hepatic Toxicity

Advise patients that they will need to undergo liver function monitoring periodically. Advise patients to immediately report any symptoms of a liver problem [e.g., skin or the whites of eyes turn yellow, urine turns dark or brown (tea colored), pain on the right side of stomach, bleeds or bruises more easily than normal, lethargy] . …

Warnings & precautions

Do not take this medicine if: None.

Diarrhea has resulted in dehydration with or without renal impairment across the clinical experience; some cases were fatal. Grade 3 to 4 diarrhea occurred in 697 (16%) of the 4257 patients who received afatinib across 44 clinical trials. In LUX-Lung 3, diarrhea occurred in 96% of patients treated with afatinib (n=229), of which 15% were Grade 3 in severity and occurred within the first 6 weeks. Renal impairment as a consequence of diarrhea occurred in 6% of patients treated with afatinib, of which 1.3% were Grade 3. In LUX-Lung 8, diarrhea occurred in 75% of patients treated with afatinib (n=392), of which 10% were Grade 3 in severity and 0.8% were Grade 4 in severity. Renal impairment as a consequence of diarrhea occurred in 7% of patients treated with afatinib, of which 2% were Grade 3 .

For patients who develop prolonged Grade 2 diarrhea lasting more than 48 hours or greater than or equal to Grade 3 diarrhea, withhold afatinib until diarrhea resolves to Grade 1 or less and resume afatinib with appropriate dose reduction . Provide patients with an anti-diarrheal agent (e.g., loperamide) for self-administration at the onset of diarrhea and instruct patients to continue anti-diarrheal therapy until loose bowel movements cease for 12 hours.

Grade 3 cutaneous reactions characterized by bullous, blistering, and exfoliating skin lesions, occurred in 0.2% of the 4257 patients who received afatinib across clinical trials. In LUX-Lung 3, the overall incidence of cutaneous reactions consisting of rash, erythema, and acneiform rash was 90%, and the incidence of Grade 3 cutaneous reactions was 16%. In addition, the incidence of Grade 1 to 3 palmar-plantar erythrodysesthesia syndrome was 7%. …

Afatinib side effects

The following clinically significant adverse reactions are described elsewhere in the labeling:

• Diarrhea

• Bullous and Exfoliative Skin Disorders

• Interstitial Lung Disease

• Hepatic Toxicity

• Gastrointestinal Perforation

• Keratitis

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The data in the Warnings and Precautions section reflect exposure to afatinib for clinically significant adverse reactions in 4257 patients enrolled in LUX-Lung 3 (n=229) and LUX-Lung 8 (n=392), and 3636 patients with cancer enrolled in 42 studies of afatinib administered alone or in combination with other anti-neoplastic drugs at afatinib doses ranging from 10 to 70 mg daily or at doses 10 to 160 mg in other regimens. The mean exposure was 5.5 months. The population included patients with various cancers, the most common of which were NSCLC, breast, colorectal, brain, and head and neck.

The data described below reflect exposure to afatinib as a single agent in LUX-Lung 3, a randomized, active-controlled trial conducted in patients with EGFR mutation-positive, metastatic NSCLC, and in LUX-Lung 8, a randomized, active-controlled trial in patients with metastatic squamous NSCLC progressing after platinum-based chemotherapy. …

Drug interactions

Effect of P-glycoprotein (P-gp) Inhibitors and Inducers

Concomitant taking of P-gp inhibitors (including but not limited to ritonavir, cyclosporine A, ketoconazole, itraconazole, erythromycin, verapamil, quinidine, tacrolimus, nelfinavir, saquinavir, and amiodarone) with afatinib can increase exposure to afatinib . Reduce afatinib daily dose as recommended .

Concomitant taking of P-gp inducers (including but not limited to rifampicin, carbamazepine, phenytoin, phenobarbital, and St. John’s wort) with afatinib can decrease exposure to afatinib

. Increase afatinib daily dose as recommended [s

ee Dosage and Administration (

2.5)

].

About this medicine

Afatinib tablets contain afatinib, a tyrosine kinase inhibitor which is a 4-anilinoquinazoline. Afatinib is presented as the dimaleate salt, with the chemical name 2-butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-,(2E)-,(2Z)-2-butenedioate(1:2). Its structural formula is:

Afatinib dimaleate is an off-white to yellow color, hygroscopic powder, slightly soluble in dimethyl sulfoxide, dimethylformamide and very slightly soluble in water, with an empirical formula of C

24H

25ClFN

5O

3.2C

4H

4O

4(1:2), and a relative molecular mass of 718.09.

Afatinib tablets for oral administration are available in 40 mg, 30 mg, or 20 mg of afatinib (equivalent to 59.12 mg, 44.34 mg, or 29.56 mg afatinib dimaleate, respectively). The inactive ingredients of afatinib tablets are the following: Tablet Core: colloidal silicon dioxide, crospovidone, lactose monohydrate, magnesium stearate, microcrystalline cellulose and Coating: hypromellose, polyethylene glycol, polysorbate 80, talc and titanium dioxide. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID ec5b9e00-3eab-4dbd-9bb3-75865b1af485. Read the full official label on DailyMed.

Related medicines

Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate